Mariana Laureano de Souza

Dr. Mariana Laureano de Souza

Rutgers New Jersey Medical School
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SXStanley C. Xie
Stanley C. Xie
YWYinuo Wang
Yinuo Wang
CMCraig Morton
Craig Morton
RMRiley D. Metcalfe
Riley D. Metcalfe
CDCon Dogovski
Con Dogovski
LTLeann Tilley
Leann Tilley
Malaria poses an enormous threat to human health. With ever increasing resistance to currently deployed drugs, breakthrough compounds with novel mechanisms of action are urgently needed. Here, we explore pyrimidine-based sulfonamides as a new low molecular weight inhibitor class with drug-like physical parameters and a synthetically accessible scaffold. We show that the exemplar, OSM-S-106, has potent activity against parasite cultures, low mammalian cell toxicity and low propensity for resistance development. In vitro evolution of resistance using a slow ramp-up approach pointed to the Plasmodium falciparum cytoplasmic asparaginyl-tRNA synthetase (PfAsnRS) as the target, consistent with our finding that OSM-S-106 inhibits protein translation and activates the amino acid starvation response. Targeted mass spectrometry confirms that OSM-S-106 is a pro-inhibitor and that inhibition of PfAsnRS occurs via enzyme-mediated production of an Asn-OSM-S-106 adduct. Human AsnRS is much less susceptible to this reaction hijacking mechanism. X-ray crystallographic studies of human AsnRS in complex with inhibitor adducts and docking of pro-inhibitors into a model of Asn-tRNA-bound PfAsnRS provide insights into the structure-activity relationship and the selectivity mechanism.

7 May 2024 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
SMSilvane Maria Fonseca Murta
Silvane Maria Fonseca Murta
PSPedro Augusto Lemos Santana
Pedro Augusto Lemos Santana
TLThibault Joseph William Jacques Dit Lapierre
Thibault Joseph William Jacques Dit Lapierre
APAndré Berndt Penteado
André Berndt Penteado
MHMarissa El Hajje
Marissa El Hajje
RFRafaela Salgado Ferreira
Rafaela Salgado Ferreira
Benznidazole, the drug of choice for treating Chagas Disease (CD), has significant limitations, such as poor cure efficacy, mainly in the chronic phase of CD, association with side effects, and parasite resistance. Understanding parasite resistance to benznidazole is crucial for developing new drugs to treat CD. Here, the authors review the current understanding of the molecular basis of benznidazole resistance. Furthermore, they discuss the state-of-the-art methods and critical outcomes employed to evaluate the efficacy of potential drugs against T. cruzi, aiming to select better compounds likely to succeed in the clinic. Finally, the authors describe the different strategies employed to overcome resistance to benznidazole and find effective new treatments for CD. Resistance to benznidazole is a complex phenomenon that occurs naturally among T. cruzi strains. The combination of compounds that inhibit different metabolic pathways of the parasite is an important strategy for developing a new chemotherapeutic protocol.

3 October 2023 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
MSMariana Laureano de Souza
Mariana Laureano de Souza
TLThibault Joseph William Jacques Dit Lapierre
Thibault Joseph William Jacques Dit Lapierre
GMGabriel Vitor de Lima Marques
Gabriel Vitor de Lima Marques
WFWitor Ribeiro Ferraz
Witor Ribeiro Ferraz
APAndré Berndt Penteado
André Berndt Penteado
RFRafaela Salgado Ferreira
Rafaela Salgado Ferreira
Chagas disease (CD) imposes social and economic burdens, yet theavailable treatments have limited efficacy in the disease's chronic phase andcause serious adverse effects. To address this challenge, target-basedapproaches are a possible strategy to develop new, safe, and active treatments for both phases of the disease. This review delves into target-basedapproaches applied to CD drug discovery, emphasizing the studies from the lastfive years. We highlight the proteins cruzain (CZ), trypanothionereductase (TR), sterol 14 α-demethylase (CPY51), iron superoxide dismutase(Fe-SOD), proteasome, cytochrome b (Cytb), and cleavage and polyadenylationspecificity factor 3 (CPSF3), chosen based on their biological andchemical validation as drug targets. For each, wediscuss its biological relevance and validation as a target, currently relatedchallenges, and the status of the most promising inhibitors. Target-based approaches toward developing potentialCD therapeutics have yielded promising leads in recent years. We expect asignificant advance in this field in the next decade, fueled by the new optionsfor Trypanosoma cruzi genetic manipulation that arose in the pastdecade, combined with recent advances in computational chemistry and chemicalbiology.

15 April 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
AMAlex R. Medeiros
Alex R. Medeiros
LFLeonardo Ferreira
Leonardo Ferreira
MSMariana Laureano de Souza
Mariana Laureano de Souza
celso de oliveira Rezende Júniorcelso de oliveira Rezende Júnior
celso de oliveira Rezende Júnior
RERocío Marisol Espinoza-Chávez
Rocío Marisol Espinoza-Chávez
AAAdriano Andricopulo
Adriano Andricopulo
Natural products based on imidazole scaffolds have inspired the discovery of a wide variety of bioactive compounds. Herein, a series of imidazoles that act as competitive and potent cruzain inhibitors was investigated using a combination of ligand- and structure-based drug design strategies. Quantitative structure–activity relationships (QSARs) were generated along with the investigation of enzyme–inhibitor molecular interactions. Predictive hologram QSAR (HQSAR, r2pred = 0.80) and AutoQSAR (q2 = 0.90) models were built, and key structural properties that underpin cruzain inhibition were identified. Moreover, comparative molecular field analysis (CoMFA, r2pred = 0.81) and comparative molecular similarity indices analysis (CoMSIA, r2pred = 0.73) revealed 3D molecular features that strongly affect the activity of the inhibitors. These findings were examined along with molecular docking studies and were highly compatible with the intermolecular contacts that take place between cruzain and the inhibitors. The results gathered herein revealed the main factors that determine the activity of the imidazoles studied and provide novel knowledge for the design of improved cruzain inhibitors.

12 January 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LWLushun Wang
Lushun Wang
MBMonica J. Bohmer
Monica J. Bohmer
JWJinhua Wang
Jinhua Wang
FNFlore Nardella
Flore Nardella
JCJaeson Calla
Jaeson Calla
NGNathanael S. Gray
Nathanael S. Gray

23 February 2022 in ChemBioChem
Verified
Journal Article
Open access
PDF file
TETyler Eck
Tyler Eck
MSMariana Laureano de Souza
Mariana Laureano de Souza
MDMelvin Delvillar
Melvin Delvillar
KAKutub Ashraf
Kutub Ashraf
RBRammohan R. Yadav Bheemanaboina
Rammohan R. Yadav Bheemanaboina
NGNina Goodey
Nina Goodey
Plasmodium falciparum cGMP‐dependent protein kinase (PfPKG) is an enticing antimalarial drug target. Novel chemotypes are needed because existing inhibitors have safety issues that may prevent further development. This work demonstrates isoxazole‐based compounds are potent ATP competitive inhibitors of PfPKG and discloses a new analogue in this series. Isoxazoles 3 and 5 had Ki values that are comparable to a known standard, 4‐[2‐(4‐fluorophenyl)‐5‐(1‐methylpiperidine‐4‐yl)‐1H pyrrol‐3‐yl] pyridine. They also exhibited excellent selectivity for PfPKG over the human orthologue and the gatekeeper mutant T618Q PfPKG, which mimics the less accessible binding site of the human orthologue. The human orthologue's larger binding site volume is predicted to explain the selectivity of the inhibitors for the P. falciparum enzyme.